NervGen Pharma ( (TSE:NGEN) ) just unveiled an announcement.
NervGen Pharma Corp. has initiated an expanded access policy for its investigational product NVG-291, allowing individuals with spinal cord injuries who participated in its clinical trials to continue treatment. This decision follows a request from a physician and approval from the FDA to proceed with the expanded access protocol. The policy aims to provide treatment opportunities for those with unmet medical needs, while the company continues its Phase 1b/2a clinical trial to evaluate NVG-291’s efficacy and safety.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biotech company focused on developing neurorestorative therapeutics. The company is dedicated to creating treatments for spinal cord injuries and holds exclusive worldwide rights to NVG-291, a therapeutic peptide targeting nervous system repair.
YTD Price Performance: -20.69%
Average Trading Volume: 46,756
Technical Sentiment Signal: Hold
Current Market Cap: $129.8M
For a thorough assessment of NGEN stock, go to TipRanks’ Stock Analysis page.